Key Takeaways
- Resilient quarter, margin pressure ahead: Domestic volumes were flat and Boroplus declined 18%, yet EBITDA grew 1% and PAT surged 4.1x on a one-off MAT credit of ₹288 Crores. Gross margin contracted only 30 bps in Q4, but management guided for a ~200 bps hit in Q1 FY23 as higher-cost inventory flows through.
- Premium and discretionary portfolios under strain: Kesh King declined 7% and Male Grooming de-grew as inflation squeezed premium products and COVID kept social events shut. Management sees no structural issue, citing a 16% two-year CAGR for Kesh King, and expects a rebound as markets normalize.
- Distribution engine is the offensive play: Project Khoj added 8,000 rural towns, the rural field force expanded 50%, and modern trade and e-com grew 9% and 90% respectively. Management is protecting these investments, with no budget cuts despite the tough environment.
- The Dermicool acquisition and new-age bets are early-stage growth options: Dermicool revenue started consolidating in April, but distribution integration is a year away. Investments in Helios and an F&B startup are small today, with no forward scale targets given.
- What to watch next quarter: Whether the promised Q2 rural demand bounce materializes, the actual Q1 gross margin print against the 200 bps guidance, and any progress on reducing the promoter pledge level.
Demand & Volume Environment
- Flat volumes, mixed portfolio: Domestic volumes were flat YoY as rural demand stayed subdued and inflation hurt wallets across urban and rural markets. The pain was uneven: Pain Management grew on the Omicron tailwind, while Boroplus fell 18% and discretionary Male Grooming de-grew with schools and social events still closed.
- Premium stress is cyclical, not structural: Kesh King's 7% decline sits against a 45% growth base quarter; its two-year CAGR is 16%. Management noted that all costly premium products are under pressure right now, and expects double-digit long-term growth to resume once the market normalizes.
- Downtrading is real but manageable: LUPs contribute only 23%-24% of Emami's business, so the company sees no portfolio gaps from the shift. No significant LUP growth was observed because inflation is hitting that segment too.
- The summer portfolio is the near-term bright spot: April and May showed good traction for Navratna and the summer range, aided by an extreme summer. Management has taken an aggressive stance on advertising for the summer portfolio because markets have opened up after two years.
Mohan Goenka: "we are very optimist that Q2 there should be some bounce back for sure."
Margins: The Q1 Cliff and the Recovery Path
- Q4 held up, Q1 takes the hit: Gross margin contracted only 30 bps to 62.4% in Q4 because price hikes and strategic procurement offset raw material inflation. But the material consumed in Q4 was older, lower-cost inventory; new purchases at prevailing market prices will hit Q1, driving an expected ~200 bps gross margin contraction even after factoring in 4.5% price hikes already taken.
- Input costs have peaked: Management stated that input prices have now stabilized and are not rising further. The recovery math is straightforward: two quarters of decline, then benefit starts flowing from Q3 and Q4, with a bounce back to the original 70%-72% gross margin level once markets stabilize and a downtrend in input costs appears.
- Ad spend stays elevated: Higher Q4 advertising spend was driven by new launches and the ongoing Zandu Care cost. On a full-year basis, ad spend has been maintained, not increased significantly, and no cuts are planned for the coming year because the strategy is to invest for growth.
Mohan Goenka: "once the market stabilizes and we see a down trend you would see again we bounce back to our original 70%-72% gross margin levels... I think it is just a matter of about two quarters where we would see this kind of a decline, then we will see a benefit coming in from Q3 and Q4."
Distribution & Channel Transformation
- Project Khoj is the rural spearhead: The initiative added 8,000 towns last year, taking total coverage to 40,000 towns and now 42,000. Business KPIs on new town additions are running at 95% accuracy, achieved through a potential-based approach to identify gaps and appoint distributors. The rural field force was expanded by almost 50%.
- No austerity here: Despite inflation, low sales, and a weak rural environment, management has not cut a single budget for Project Khoj, SAMT expansion in chemist outlets, or other identified opportunities. The next agenda is to juice out towns added in the last nine months, then add another 8,000 to 10,000 villages in the second half.
- Modern trade and e-com are scaling fast: Modern trade grew 9% and e-com surged 90%, with e-com salience reaching 7.1% of domestic revenues and modern trade at 8.4%. Large packs and combos have become significant growth drivers, and Joint Business Plans have made Emami a preferred supplier in many large accounts.
- Healthcare distribution is building: The healthcare range activated approximately 32,000 additional outlets across Ayurvedic Bhandar and chemist channels, reaching 1.1 lakh outlets. The Health Juice range and Ayurvedic costume launch both ramped up well.
Vinod Rao: "we share the table with a lights of Colgate and such company lot of top to top engagements, I think these are all learnings which has helped us drive growth both in e-com and modern trade."
Brand Portfolio: Hits, Misses, and Relaunches
| Brand / Segment | Trend | Commentary |
|---|---|---|
| Pain Management | ▲ Grew 18% | Benefited from the Omicron wave in Q4; concern noted on the very high base going forward. |
| 7 Oils in One | ▲ Grew 29% | Seeing significant growth continuously quarter-on-quarter. |
| Navaratna | ▬ Flat (Q4), ▲ Apr-May | Flat in Q4 on a high COVID base; two-year CAGR of 13%. April and May have been good due to extreme summer; management confident it will deliver significantly well. |
| Kesh King | ▼ Declined 7% | High base effect (45% growth in base quarter); two-year CAGR of 16%. Recent pricing pressure from inflation in the last two to three months. Management sees no product or off-take issue. |
| Boroplus | ▼ Declined 18% | Specific reason not detailed beyond the challenging macro and subdued consumption. |
| Male Grooming | ▼ De-grew | Discretionary range hit by COVID keeping schools, colleges, and social events shut for two years. April and May showing good growth as things open up; Fair & Handsome relaunch planned. |
| Healthcare | ▲ Grew 9% | Health Juice range ramped up well; D2C platform launches showing green shoots; generics and ethical business growing much better than competition. |
- Market share gains across the board: Management stated that market share increased in almost all portfolios and categories over the last two challenging years. The focus now is shifting from defending share to growing the markets.
- Hair oil strategy is focused, not fragmented: The company will focus on its existing three hair oil brands; any new launches would be premium offerings mostly on the e-com platform.
New Bets: Dermicool, Start-ups, and the South
- Dermicool integration is a FY24 story: The brand was acquired in March and revenues started consolidating from April, but it is still selling from its own network. Distribution will transition to Emami's network only from next year. Inventory build for Dermicool contributed to the increase in inventory days.
- Start-up investments are small and unguided: Helios (approximately ₹80 Cr topline) is expected to continue doing well, but management declined to provide forward-looking scale targets for the next two to four years. The F&B start-up investment is similarly early-stage. Learnings from these engagements were described in general terms around democratization of investments and pack/format choices, without specific functional improvements quantified.
- South India remains a long grind: The company will keep investing in Andhra, Telangana, Tamil Nadu, and Karnataka despite challenges, but acknowledged that the larger potential still lies in the North and West.
International Business & One-offs
- International grew 8% despite the CIS drag: Excluding the CIS region, which was impacted by the Russia-Ukraine conflict, international business grew 17%. Key geographies Bangladesh and UAE performed well. Management expects double-digit growth from next quarter onwards despite the geopolitical situation.
- MAT credit flatters the PAT line: The recognition of MAT credit entitlement of ₹288 Crores drove PAT to ₹356 Crores, a 4.1x increase. The company will pay MAT next year, with an overall tax rate of roughly 18%-19%, and MAT credit generation could bring that down by 1%-2%.
- One-off Forex loss: PBT declined 15% to ₹104 Crores, partly due to a one-off Forex loss of ₹5.1 Crores and lower other income.
- Kesh King amortization nears end: Amortization on the Kesh King acquisition will complete in Q1 June, after which only Dermicool and other brand amortizations will continue.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Gross margin pressure | ~200 bps contraction in Q1 FY23 post price hikes | Q1 FY23 |
| Gross margin recovery | Bounce back to original 70%-72% levels once input costs trend down | Q3 and Q4 FY23 (benefit starts) |
| Rural demand recovery | "Some bounce back for sure" | Q2 FY23 |
| International growth | Double-digit growth despite Russia-Ukraine situation | From Q2 FY23 onwards |
| Project Khoj store expansion | Reach 75,000 stores; add another 8,000-10,000 villages in H2 | 75,000 stores by H1 FY23; villages in H2 |
| Dermicool distribution integration | Transition to Emami's distribution network | Next year (FY24) |
| Kesh King amortization | Amortization completes | Q1 FY23 (June) |
| Advertising budgets | No cuts planned; invest whatever is needed for growth | FY23 |
| CEO appointment | No definite plan; will communicate if it happens | Undated |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Consolidated revenue | ₹770 cr, +5% YoY, two-year CAGR 20% |
| India business revenue growth | +4% YoY, two-year CAGR 22%, flat volume growth |
| Gross margin | 62.4%, contracted 30 bps YoY |
| EBITDA | ₹164 cr, +1% YoY |
| Profit before tax | ₹104 cr, -15% YoY; includes one-off forex loss of ₹5.1 cr and lower other income |
| PAT | ₹356 cr, +4.1x YoY; includes MAT credit recognition of ₹288 cr |
| FY22 consolidated revenue | ₹3,192 cr, +11% YoY |
| FY22 EBITDA | ₹952 cr, +8% YoY |
| FY22 PAT | ₹839 cr, +85% YoY |
| FY22 three-year profit before tax CAGR | 20% |
| Q1 FY23 expected gross margin pressure | ~200 bps contraction, post price hikes |
| Price increase taken | 4.5% overall; 7%–8% on packs where increases were taken |
| International business revenue growth | +8% YoY on a high base of +28%; excluding CIS, +17% |
| E-com channel growth | +90% YoY; salience at 7.1% of domestic revenues |
| Modern trade growth | +9% YoY; salience at 8.4% of domestic revenues, +60 bps |
| CSD revenue growth | +32% YoY |
| Pain management range growth | +9% YoY |
| Healthcare range growth | +4% YoY |
| Male grooming range growth | +4% YoY |
| 7 Oils in One growth | +8% YoY |
| Navaratna growth | Flat YoY; two-year CAGR 13%, three-year CAGR 4% |
| Kesh King growth | -7% YoY on a high base of +45%; two-year CAGR 16% |
| Boroplus growth | -18% YoY |
| Project Khoj rural towns coverage | 40,000 towns, +8,000 in Q4; now at 42,000 |
| Healthcare products outlets | 1.1 lakh outlets, +32,000 activated |
| Standalone modern trade outlets | 3,300+ outlets across 40 cities |
| LUP contribution to total business | 23%–24% |
| Rural-urban mix | Rural 54%–55% |
| Pledge level | 34% |
| Expected FY23 brand amortization | ~₹85 cr annually after Kesh King amortization ends in Q1 |
| Expected FY23 tax rate | 18%–19%, with MAT credit potentially reducing it by 1–2 ppt |